These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35226416)

  • 1. Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling.
    Barbacki A; Baron M; Wang M; Zhang Y; Stevens W; Sahhar J; Proudman S; Nikpour M; Man A;
    Arthritis Care Res (Hoboken); 2023 Mar; 75(3):640-647. PubMed ID: 35226416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of damage trajectories in systemic sclerosis using group-based trajectory modelling.
    Baron M; Barbacki A; Man A; de Vries-Bouwstra JK; Johnson D; Stevens W; Osman M; Wang M; Zhang Y; Sahhar J; Ngian GS; Proudman S; Nikpour M;
    Rheumatology (Oxford); 2023 Sep; 62(9):3059-3066. PubMed ID: 36625513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anemia Is an Indicator for Worse Organ Damage Trajectories in Patients with Systemic Sclerosis: A Retrospective Study.
    Li Z; Xu D; Jiang X; Li T; Su Y; Mu R
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term organ damage accrual and late mortality in systemic sclerosis.
    Lazzaroni MG; Moschetti L; Breda M; Franceschini F; Airò P
    Clin Exp Rheumatol; 2023 Oct; ():. PubMed ID: 37933549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
    Ferdowsi N; Huq M; Stevens W; Hudson M; Wang M; Tay T; Burchell JL; Mancuso S; Rabusa C; Sundararajan V; Prior D; Proudman SM; Baron M; Nikpour M; ;
    Ann Rheum Dis; 2019 Jun; 78(6):807-816. PubMed ID: 30928903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.
    Zheng B; Wang M; Stevens W; Proudman S; Nikpour M; Baron M; ;
    Semin Arthritis Rheum; 2022 Apr; 53():151973. PubMed ID: 35149318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.
    Nikpour M; Hissaria P; Byron J; Sahhar J; Micallef M; Paspaliaris W; Roddy J; Nash P; Sturgess A; Proudman S; Stevens W
    Arthritis Res Ther; 2011; 13(6):R211. PubMed ID: 22189167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.
    Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin R; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold J
    Arthritis Rheum; 1999 Nov; 42(11):2372-80. PubMed ID: 10555033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.
    Nevskaya T; Baron M; Pope JE;
    Rheumatology (Oxford); 2017 Jul; 56(7):1111-1122. PubMed ID: 28340090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling.
    Man A; Davidyock T; Ferguson LT; Ieong M; Zhang Y; Simms RW
    Rheumatology (Oxford); 2015 Aug; 54(8):1464-71. PubMed ID: 25784774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects.
    Diab S; Dostrovsky N; Hudson M; Tatibouet S; Fritzler MJ; Baron M; Khalidi N;
    J Rheumatol; 2014 Nov; 41(11):2179-85. PubMed ID: 25274885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG).
    Fan X; Pope J; ; Baron M
    Rheumatol Int; 2010 Jul; 30(9):1205-10. PubMed ID: 19777240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
    Baron M; Hudson M; Steele R; Lo E;
    J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low socioeconomic status (measured by education) and outcomes in systemic sclerosis: data from the Canadian Scleroderma Research Group.
    Mansour S; Bonner A; Muangchan C; Hudson M; Baron M; Pope JE;
    J Rheumatol; 2013 Apr; 40(4):447-54. PubMed ID: 23418377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis.
    Steen VD; Medsger TA
    Arthritis Rheum; 1997 Jun; 40(6):1146-51. PubMed ID: 9182926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry.
    Khimdas S; Harding S; Bonner A; Zummer B; Baron M; Pope J;
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):142-9. PubMed ID: 20740608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for morphea.
    Albuquerque JV; Andriolo BN; Vasconcellos MR; Civile VT; Lyddiatt A; Trevisani VF
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD005027. PubMed ID: 31309547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE).
    Carbonell C; Marcos M; Guillén-Del-Castillo A; Rubio-Rivas M; Argibay A; Marín-Ballvé A; Rodríguez-Pintó I; Baldà-Masmiquel M; Callejas-Moraga E; Colunga D; Sáez-Comet L; González-Echávarri C; Ortego-Centeno N; Marí-Alfonso B; Vargas-Hitos JA; Todolí-Parra JA; Trapiella L; Herranz-Marín MT; Freire M; Castro-Salomó A; Perales-Fraile I; Madroñero-Vuelta AB; Sánchez-García ME; Ruiz-Muñoz M; González-García A; Sánchez-Redondo J; de-la-Red-Bellvis G; Fernández-Luque A; Muela-Molinero A; Lledó GM; Tolosa-Vilella C; Fonollosa-Pla V; Chamorro AJ; Simeón-Aznar CP;
    Autoimmun Rev; 2022 Oct; 21(10):103167. PubMed ID: 35931315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.
    Gelber AC; Manno RL; Shah AA; Woods A; Le EN; Boin F; Hummers LK; Wigley FM
    Medicine (Baltimore); 2013 Jul; 92(4):191-205. PubMed ID: 23793108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.